BH vs BH-A

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong recent price performance (+110.4% over 1Y), the stock trades at an extremely high P/E of 217.27 versus negative Forward P/E, signaling earnings deterioration. Profitability metrics are concerning, with a mere 0.54% net margin and 0.35% ROE, well below sector averages. While the balance sheet shows a healthy current ratio and low Price/Book of 0.50, these are overshadowed by unsustainable valuation and weak earnings momentum.

The Advanced Deterministic Scorecard reveals a weak fundamental health with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full solvency assessment. Despite strong revenue growth (10.3%) and solid balance sheet metrics (Current Ratio: 2.83, Debt/Equity: 0.60), the company's profitability is alarmingly thin (0.54% net margin, 0.35% ROE) and the P/E ratio of 227.28 is drastically elevated compared to sector averages. The stock trades at a massive premium to its Graham Number of $474.68, with a current price of $2,434.13, suggesting severe overvaluation. While insider sentiment is neutral and recent price momentum is strong, the lack of earnings growth visibility, inconsistent earnings surprises, and deteriorating ROE raise serious concerns about sustainability.